Revisiting the role of erythropoietin for treatment of ocular disorders

Erythropoietin (EPO) is a glycoprotein hormone conventionally thought to be responsible only in producing red blood cells in our body. However, with the discovery of the presence of EPO and EPO receptors in the retinal layers, the EPO seems to have physiological roles in the eye. In this review, we...

Full description

Saved in:
Bibliographic Details
Published in:Eye (London) 2016-10, Vol.30 (10), p.1293-1309
Main Authors: Shirley Ding, S L, Leow, S N, Munisvaradass, R, Koh, E H, Bastion, M L C, Then, K Y, Kumar, S, Mok, P L
Format: Article
Language:English
Subjects:
631/80/304
692/699/3161
Erythropoietin - physiology
Erythropoietin - therapeutic use
Eye Diseases - drug therapy
Eye Diseases - etiology
Eye Diseases - physiopathology
Eye Diseases - prevention & control
Humans
Laboratory Medicine
Medicine
Medicine & Public Health
Ophthalmology
Pharmaceutical Sciences/Technology
Review
Surgery
Surgical Oncology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c479t-e16303575a15cd2ca9bfcf498a54579bead7099f1de23bf83d1021f6f81a0d713
cites cdi_FETCH-LOGICAL-c479t-e16303575a15cd2ca9bfcf498a54579bead7099f1de23bf83d1021f6f81a0d713
container_end_page 1309
container_issue 10
container_start_page 1293
container_title Eye (London)
container_volume 30
creator Shirley Ding, S L
Leow, S N
Munisvaradass, R
Koh, E H
Bastion, M L C
Then, K Y
Kumar, S
Mok, P L
description Erythropoietin (EPO) is a glycoprotein hormone conventionally thought to be responsible only in producing red blood cells in our body. However, with the discovery of the presence of EPO and EPO receptors in the retinal layers, the EPO seems to have physiological roles in the eye. In this review, we revisit the role of EPO in the eye. We look into the biological role of EPO in the development of the eye and the physiologic roles that it has. Apart from that, we seek to understand the mechanisms and pathways of EPO that contributes to the therapeutic and pathological conditions of the various ocular disorders such as diabetic retinopathy, retinopathy of prematurity, glaucoma, age-related macular degeneration, optic neuritis, and retinal detachment. With these understandings, we discuss the clinical applications of EPO for treatment of ocular disorders, modes of administration, EPO formulations, current clinical trials, and its future directions.
doi_str_mv 10.1038/eye.2016.94
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5129866</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1826698519</sourcerecordid><originalsourceid>FETCH-LOGICAL-c479t-e16303575a15cd2ca9bfcf498a54579bead7099f1de23bf83d1021f6f81a0d713</originalsourceid><addsrcrecordid>eNqNkUtLAzEYRYMoWh8r9zLgRtCpeUwmyUYQ8QWCIAruQjrzpY1MJzWZKfTfm1oVFReusjiHm5tchPYJHhLM5CksYEgxKYeqWEMDUogy5wUv1tEAK45zSunzFtqO8QXjBAXeRFtUUMkZpQN0_QBzF13n2nHWTSALvoHM2wzCopsEP_MOEsusD1kXwHRTaLsl91XfmJDVLvpQQ4i7aMOaJsLex7mDnq4uHy9u8rv769uL87u8KoTqciAlw4wLbgivaloZNbKVLZQ0qbJQIzC1wEpZUgNlIytZTTAltrSSGFwLwnbQ2Sp31o-mUFepTjCNngU3NWGhvXH6J2ndRI_9XHNClSzLFHD0ERD8aw-x01MXK2ga04LvoyaSCYYlpvQfKi1LJTlRST38pb74PrTpJ94topLDk3W8sqrgYwxgv3oTrJdb6rSlXm6pVZHsg-9P_XI_x0vCyUqICbVjCN8u_SPvDb_1qZ8</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1826191935</pqid></control><display><type>article</type><title>Revisiting the role of erythropoietin for treatment of ocular disorders</title><source>PubMed Central</source><creator>Shirley Ding, S L ; Leow, S N ; Munisvaradass, R ; Koh, E H ; Bastion, M L C ; Then, K Y ; Kumar, S ; Mok, P L</creator><creatorcontrib>Shirley Ding, S L ; Leow, S N ; Munisvaradass, R ; Koh, E H ; Bastion, M L C ; Then, K Y ; Kumar, S ; Mok, P L</creatorcontrib><description>Erythropoietin (EPO) is a glycoprotein hormone conventionally thought to be responsible only in producing red blood cells in our body. However, with the discovery of the presence of EPO and EPO receptors in the retinal layers, the EPO seems to have physiological roles in the eye. In this review, we revisit the role of EPO in the eye. We look into the biological role of EPO in the development of the eye and the physiologic roles that it has. Apart from that, we seek to understand the mechanisms and pathways of EPO that contributes to the therapeutic and pathological conditions of the various ocular disorders such as diabetic retinopathy, retinopathy of prematurity, glaucoma, age-related macular degeneration, optic neuritis, and retinal detachment. With these understandings, we discuss the clinical applications of EPO for treatment of ocular disorders, modes of administration, EPO formulations, current clinical trials, and its future directions.</description><identifier>ISSN: 0950-222X</identifier><identifier>EISSN: 1476-5454</identifier><identifier>DOI: 10.1038/eye.2016.94</identifier><identifier>PMID: 27285322</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>631/80/304 ; 692/699/3161 ; Erythropoietin - physiology ; Erythropoietin - therapeutic use ; Eye Diseases - drug therapy ; Eye Diseases - etiology ; Eye Diseases - physiopathology ; Eye Diseases - prevention &amp; control ; Humans ; Laboratory Medicine ; Medicine ; Medicine &amp; Public Health ; Ophthalmology ; Pharmaceutical Sciences/Technology ; Review ; Surgery ; Surgical Oncology</subject><ispartof>Eye (London), 2016-10, Vol.30 (10), p.1293-1309</ispartof><rights>Royal College of Ophthalmologists 2016</rights><rights>Copyright Nature Publishing Group Oct 2016</rights><rights>Copyright © 2016 Royal College of Ophthalmologists 2016 Royal College of Ophthalmologists</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c479t-e16303575a15cd2ca9bfcf498a54579bead7099f1de23bf83d1021f6f81a0d713</citedby><cites>FETCH-LOGICAL-c479t-e16303575a15cd2ca9bfcf498a54579bead7099f1de23bf83d1021f6f81a0d713</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5129866/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5129866/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,724,777,781,882,27905,27906,53772,53774</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27285322$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Shirley Ding, S L</creatorcontrib><creatorcontrib>Leow, S N</creatorcontrib><creatorcontrib>Munisvaradass, R</creatorcontrib><creatorcontrib>Koh, E H</creatorcontrib><creatorcontrib>Bastion, M L C</creatorcontrib><creatorcontrib>Then, K Y</creatorcontrib><creatorcontrib>Kumar, S</creatorcontrib><creatorcontrib>Mok, P L</creatorcontrib><title>Revisiting the role of erythropoietin for treatment of ocular disorders</title><title>Eye (London)</title><addtitle>Eye</addtitle><addtitle>Eye (Lond)</addtitle><description>Erythropoietin (EPO) is a glycoprotein hormone conventionally thought to be responsible only in producing red blood cells in our body. However, with the discovery of the presence of EPO and EPO receptors in the retinal layers, the EPO seems to have physiological roles in the eye. In this review, we revisit the role of EPO in the eye. We look into the biological role of EPO in the development of the eye and the physiologic roles that it has. Apart from that, we seek to understand the mechanisms and pathways of EPO that contributes to the therapeutic and pathological conditions of the various ocular disorders such as diabetic retinopathy, retinopathy of prematurity, glaucoma, age-related macular degeneration, optic neuritis, and retinal detachment. With these understandings, we discuss the clinical applications of EPO for treatment of ocular disorders, modes of administration, EPO formulations, current clinical trials, and its future directions.</description><subject>631/80/304</subject><subject>692/699/3161</subject><subject>Erythropoietin - physiology</subject><subject>Erythropoietin - therapeutic use</subject><subject>Eye Diseases - drug therapy</subject><subject>Eye Diseases - etiology</subject><subject>Eye Diseases - physiopathology</subject><subject>Eye Diseases - prevention &amp; control</subject><subject>Humans</subject><subject>Laboratory Medicine</subject><subject>Medicine</subject><subject>Medicine &amp; Public Health</subject><subject>Ophthalmology</subject><subject>Pharmaceutical Sciences/Technology</subject><subject>Review</subject><subject>Surgery</subject><subject>Surgical Oncology</subject><issn>0950-222X</issn><issn>1476-5454</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><recordid>eNqNkUtLAzEYRYMoWh8r9zLgRtCpeUwmyUYQ8QWCIAruQjrzpY1MJzWZKfTfm1oVFReusjiHm5tchPYJHhLM5CksYEgxKYeqWEMDUogy5wUv1tEAK45zSunzFtqO8QXjBAXeRFtUUMkZpQN0_QBzF13n2nHWTSALvoHM2wzCopsEP_MOEsusD1kXwHRTaLsl91XfmJDVLvpQQ4i7aMOaJsLex7mDnq4uHy9u8rv769uL87u8KoTqciAlw4wLbgivaloZNbKVLZQ0qbJQIzC1wEpZUgNlIytZTTAltrSSGFwLwnbQ2Sp31o-mUFepTjCNngU3NWGhvXH6J2ndRI_9XHNClSzLFHD0ERD8aw-x01MXK2ga04LvoyaSCYYlpvQfKi1LJTlRST38pb74PrTpJ94topLDk3W8sqrgYwxgv3oTrJdb6rSlXm6pVZHsg-9P_XI_x0vCyUqICbVjCN8u_SPvDb_1qZ8</recordid><startdate>20161001</startdate><enddate>20161001</enddate><creator>Shirley Ding, S L</creator><creator>Leow, S N</creator><creator>Munisvaradass, R</creator><creator>Koh, E H</creator><creator>Bastion, M L C</creator><creator>Then, K Y</creator><creator>Kumar, S</creator><creator>Mok, P L</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20161001</creationdate><title>Revisiting the role of erythropoietin for treatment of ocular disorders</title><author>Shirley Ding, S L ; Leow, S N ; Munisvaradass, R ; Koh, E H ; Bastion, M L C ; Then, K Y ; Kumar, S ; Mok, P L</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c479t-e16303575a15cd2ca9bfcf498a54579bead7099f1de23bf83d1021f6f81a0d713</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>631/80/304</topic><topic>692/699/3161</topic><topic>Erythropoietin - physiology</topic><topic>Erythropoietin - therapeutic use</topic><topic>Eye Diseases - drug therapy</topic><topic>Eye Diseases - etiology</topic><topic>Eye Diseases - physiopathology</topic><topic>Eye Diseases - prevention &amp; control</topic><topic>Humans</topic><topic>Laboratory Medicine</topic><topic>Medicine</topic><topic>Medicine &amp; Public Health</topic><topic>Ophthalmology</topic><topic>Pharmaceutical Sciences/Technology</topic><topic>Review</topic><topic>Surgery</topic><topic>Surgical Oncology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Shirley Ding, S L</creatorcontrib><creatorcontrib>Leow, S N</creatorcontrib><creatorcontrib>Munisvaradass, R</creatorcontrib><creatorcontrib>Koh, E H</creatorcontrib><creatorcontrib>Bastion, M L C</creatorcontrib><creatorcontrib>Then, K Y</creatorcontrib><creatorcontrib>Kumar, S</creatorcontrib><creatorcontrib>Mok, P L</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Neurosciences Abstracts</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest Biological Science Journals</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Eye (London)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Shirley Ding, S L</au><au>Leow, S N</au><au>Munisvaradass, R</au><au>Koh, E H</au><au>Bastion, M L C</au><au>Then, K Y</au><au>Kumar, S</au><au>Mok, P L</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Revisiting the role of erythropoietin for treatment of ocular disorders</atitle><jtitle>Eye (London)</jtitle><stitle>Eye</stitle><addtitle>Eye (Lond)</addtitle><date>2016-10-01</date><risdate>2016</risdate><volume>30</volume><issue>10</issue><spage>1293</spage><epage>1309</epage><pages>1293-1309</pages><issn>0950-222X</issn><eissn>1476-5454</eissn><abstract>Erythropoietin (EPO) is a glycoprotein hormone conventionally thought to be responsible only in producing red blood cells in our body. However, with the discovery of the presence of EPO and EPO receptors in the retinal layers, the EPO seems to have physiological roles in the eye. In this review, we revisit the role of EPO in the eye. We look into the biological role of EPO in the development of the eye and the physiologic roles that it has. Apart from that, we seek to understand the mechanisms and pathways of EPO that contributes to the therapeutic and pathological conditions of the various ocular disorders such as diabetic retinopathy, retinopathy of prematurity, glaucoma, age-related macular degeneration, optic neuritis, and retinal detachment. With these understandings, we discuss the clinical applications of EPO for treatment of ocular disorders, modes of administration, EPO formulations, current clinical trials, and its future directions.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>27285322</pmid><doi>10.1038/eye.2016.94</doi><tpages>17</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0950-222X
ispartof Eye (London), 2016-10, Vol.30 (10), p.1293-1309
issn 0950-222X
1476-5454
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5129866
source PubMed Central
subjects 631/80/304
692/699/3161
Erythropoietin - physiology
Erythropoietin - therapeutic use
Eye Diseases - drug therapy
Eye Diseases - etiology
Eye Diseases - physiopathology
Eye Diseases - prevention & control
Humans
Laboratory Medicine
Medicine
Medicine & Public Health
Ophthalmology
Pharmaceutical Sciences/Technology
Review
Surgery
Surgical Oncology
title Revisiting the role of erythropoietin for treatment of ocular disorders
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-21T05%3A08%3A20IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Revisiting%20the%20role%20of%20erythropoietin%20for%20treatment%20of%20ocular%20disorders&rft.jtitle=Eye%20(London)&rft.au=Shirley%20Ding,%20S%20L&rft.date=2016-10-01&rft.volume=30&rft.issue=10&rft.spage=1293&rft.epage=1309&rft.pages=1293-1309&rft.issn=0950-222X&rft.eissn=1476-5454&rft_id=info:doi/10.1038/eye.2016.94&rft_dat=%3Cproquest_pubme%3E1826698519%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c479t-e16303575a15cd2ca9bfcf498a54579bead7099f1de23bf83d1021f6f81a0d713%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1826191935&rft_id=info:pmid/27285322&rfr_iscdi=true